Pharmacokinetics of huperzine A following oral administration to human volunteers
The objective of the present study was to investigate the in vivo pharmacokinetics of huperzine A in healthy human volunteers. Twelve subjects (M 6, F 6; age ranged from 20-25 years) participated in the study. Huperzine A was administered in tablet form at a single dose of 0.4 mg. Following oral adm...
Saved in:
| Published in | European journal of drug metabolism and pharmacokinetics Vol. 32; no. 4; pp. 183 - 187 |
|---|---|
| Main Authors | , , , |
| Format | Journal Article |
| Language | English |
| Published |
Genève
Médecine et hygiène
01.10.2007
|
| Subjects | |
| Online Access | Get full text |
| ISSN | 0378-7966 2107-0180 |
| DOI | 10.1007/BF03191002 |
Cover
| Abstract | The objective of the present study was to investigate the in vivo pharmacokinetics of huperzine A in healthy human volunteers. Twelve subjects (M 6, F 6; age ranged from 20-25 years) participated in the study. Huperzine A was administered in tablet form at a single dose of 0.4 mg. Following oral administration, the presence of huperzine A started to appear in the plasma at 5-10 min, and reached the peak concentrations with a Cmax of 2.59 +/- 0.37 ng/ml at 58.33 +/- 3.89 min (time to reach peak level, Tmax. The area under plasma vs time curve (AUC(0-t)) and the area under plasma from zero to infinity (AUC(0-infinity) for huperzine A were found to be 1986.96 +/- 164.57 microg/l.min and 2450.34 +/- 233.32 microg/l.min, respectively. The results of this study indicated that the pharmacokinetics of huperzine A conformed to a two-compartmental open model. The mean values of alpha and the beta half-life were 21.13 +/- 7.28 min and 716.25 +/- 130.18 min respectively, and showed a biphasic profile with rapid distribution followed by a slower elimination rate. |
|---|---|
| AbstractList | The objective of the present study was to investigate the in vivo pharmacokinetics of huperzine A in healthy human volunteers. Twelve subjects (M 6, F 6; age ranged from 20-25 years) participated in the study. Huperzine A was administered in tablet form at a single dose of 0.4 mg. Following oral administration, the presence of huperzine A started to appear in the plasma at 5-10 min, and reached the peak concentrations with a Cmax of 2.59 +/- 0.37 ng/ml at 58.33 +/- 3.89 min (time to reach peak level, Tmax. The area under plasma vs time curve (AUC(0-t)) and the area under plasma from zero to infinity (AUC(0-infinity) for huperzine A were found to be 1986.96 +/- 164.57 microg/l.min and 2450.34 +/- 233.32 microg/l.min, respectively. The results of this study indicated that the pharmacokinetics of huperzine A conformed to a two-compartmental open model. The mean values of alpha and the beta half-life were 21.13 +/- 7.28 min and 716.25 +/- 130.18 min respectively, and showed a biphasic profile with rapid distribution followed by a slower elimination rate.The objective of the present study was to investigate the in vivo pharmacokinetics of huperzine A in healthy human volunteers. Twelve subjects (M 6, F 6; age ranged from 20-25 years) participated in the study. Huperzine A was administered in tablet form at a single dose of 0.4 mg. Following oral administration, the presence of huperzine A started to appear in the plasma at 5-10 min, and reached the peak concentrations with a Cmax of 2.59 +/- 0.37 ng/ml at 58.33 +/- 3.89 min (time to reach peak level, Tmax. The area under plasma vs time curve (AUC(0-t)) and the area under plasma from zero to infinity (AUC(0-infinity) for huperzine A were found to be 1986.96 +/- 164.57 microg/l.min and 2450.34 +/- 233.32 microg/l.min, respectively. The results of this study indicated that the pharmacokinetics of huperzine A conformed to a two-compartmental open model. The mean values of alpha and the beta half-life were 21.13 +/- 7.28 min and 716.25 +/- 130.18 min respectively, and showed a biphasic profile with rapid distribution followed by a slower elimination rate. The objective of the present study was to investigate the in vivo pharmacokinetics of huperzine A in healthy human volunteers. Twelve subjects (M 6, F 6; age ranged from 20-25 years) participated in the study. Huperzine A was administered in tablet form at a single dose of 0.4 mg. Following oral administration, the presence of huperzine A started to appear in the plasma at 5-10 min, and reached the peak concentrations with a Cmax of 2.59 +/- 0.37 ng/ml at 58.33 +/- 3.89 min (time to reach peak level, Tmax. The area under plasma vs time curve (AUC(0-t)) and the area under plasma from zero to infinity (AUC(0-infinity) for huperzine A were found to be 1986.96 +/- 164.57 microg/l.min and 2450.34 +/- 233.32 microg/l.min, respectively. The results of this study indicated that the pharmacokinetics of huperzine A conformed to a two-compartmental open model. The mean values of alpha and the beta half-life were 21.13 +/- 7.28 min and 716.25 +/- 130.18 min respectively, and showed a biphasic profile with rapid distribution followed by a slower elimination rate. |
| Author | Li, Y. X. Zhang, R. Q. Jiang, X. H. Li, C. R. |
| Author_xml | – sequence: 1 givenname: Y. X. surname: Li fullname: Li, Y. X. – sequence: 2 givenname: R. Q. surname: Zhang fullname: Zhang, R. Q. – sequence: 3 givenname: C. R. surname: Li fullname: Li, C. R. – sequence: 4 givenname: X. H. surname: Jiang fullname: Jiang, X. H. |
| BackLink | http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=20050279$$DView record in Pascal Francis https://www.ncbi.nlm.nih.gov/pubmed/18348466$$D View this record in MEDLINE/PubMed |
| BookMark | eNpt0UsvBTEUB_BGCNdj4wPIbFhIhtPp9DFLxCuRIGE96e20lE57tTOET6-4SMTZ9KT5nbP4n1W06IPXCG1i2MMAfP_wBAhuclstoEmFgZeABSyiCRAuSt4wtoI2UnqAXEQ0lLJltIIFqUXN2ARdX93L2EsVHq3Xg1WpCKa4H2c6vuWP4qAwwbnwYv1dEaJ0hex6620aohxs8MUQMu6lL56DG_2gdUzraMlIl_TG_F1DtyfHN0dn5cXl6fnRwUWpCKZDKSgDDhUznFadoqomvAFTE6bktOsa0cmK1UxpAtooQTRRMo9gYlQ9lUQIsoZ2vvbOYngadRra3ialnZNehzG1HDCmFFiGW3M4TnvdtbNoexlf2-8QMtieA5mUdCZKr2z6cRUAhYo32e1-ORVDSlGb31XQfhyj_T1GxvAHKzt8hpazs-6_kXeUaYo5 |
| CitedBy_id | crossref_primary_10_1016_j_jep_2023_116740 crossref_primary_10_1007_s11596_017_1807_8 crossref_primary_10_1002_bmc_6011 crossref_primary_10_1021_acs_chemrestox_4c00418 crossref_primary_10_3390_ph16081061 crossref_primary_10_1016_j_ejphar_2019_172851 crossref_primary_10_1089_neu_2017_5258 crossref_primary_10_52547_phypha_26_4_7 crossref_primary_10_1111_epi_13634 crossref_primary_10_1016_j_mehy_2016_12_006 crossref_primary_10_31482_mmsl_2019_016 crossref_primary_10_1007_s10337_011_2037_z crossref_primary_10_1016_j_bbrc_2016_10_039 crossref_primary_10_1002_cbdv_201000269 crossref_primary_10_1007_s12013_011_9258_5 crossref_primary_10_1038_aps_2016_24 crossref_primary_10_1080_14737175_2016_1175303 crossref_primary_10_1093_ijnp_pyv098 crossref_primary_10_1517_13543776_2012_701620 crossref_primary_10_1007_s11101_014_9384_y crossref_primary_10_1186_s12967_024_04908_2 |
| Cites_doi | 10.1002/jnr.490240220 10.1016/S0091-3057(03)00111-4 10.1016/j.jchromb.2004.01.013 10.1002/bmc.709 10.1139/v86-137 10.1002/rcm.1384 |
| ContentType | Journal Article |
| Copyright | 2008 INIST-CNRS |
| Copyright_xml | – notice: 2008 INIST-CNRS |
| DBID | AAYXX CITATION IQODW CGR CUY CVF ECM EIF NPM 7X8 |
| DOI | 10.1007/BF03191002 |
| DatabaseName | CrossRef Pascal-Francis Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic MEDLINE |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Pharmacy, Therapeutics, & Pharmacology |
| EISSN | 2107-0180 |
| EndPage | 187 |
| ExternalDocumentID | 18348466 20050279 10_1007_BF03191002 |
| Genre | Clinical Trial Research Support, Non-U.S. Gov't Journal Article |
| GroupedDBID | --- .GJ 06D 0R~ 0VY 1N0 2.D 2KG 2VQ 30V 4.4 406 408 40D 53G 5GY 67N 96X AAAUJ AABHQ AACDK AAEWM AAIAL AAIKX AAJKR AANXM AANZL AARHV AARTL AASML AATNV AAWCG AAYIU AAYQN AAYTO AAYXX AAYZH AAZMS ABAKF ABBRH ABDBE ABDZT ABFSG ABFTV ABHLI ABJNI ABJOX ABKCH ABKMS ABPLI ABQBU ABRTQ ABTKH ABTMW ABWHX ABXPI ACAOD ACBXY ACCOQ ACDTI ACGFS ACKNC ACMLO ACPIV ACSTC ACZOJ ADHHG ADHIR ADKPE ADRFC ADURQ ADYPR ADZKW AEBTG AEFQL AEGNC AEJHL AEJRE AEKMD AEMSY AENEX AEOHA AEPYU AESKC AETCA AEVLU AEXYK AEYRQ AEZWR AFBBN AFDZB AFHIU AFLOW AFOHR AFWTZ AFZKB AGAYW AGDGC AGJBK AGQEE AGQMX AGRTI AGWZB AGYKE AHAVH AHBYD AHSBF AHWEU AHYZX AIAKS AIGIU AIIXL AILAN AIXLP AJBLW AJRNO ALFXC ALMA_UNASSIGNED_HOLDINGS AMKLP AMXSW AMYLF AMYQR ANMIH ASPBG ATHPR AVWKF AWSVR AXYYD AYFIA AZFZN BBWZM BGNMA CITATION CSCUP DNIVK DPUIP DU5 EBLON EBS EIOEI EJD EN4 ESBYG F5P FEDTE FERAY FFXSO FIGPU FLLZZ FNLPD FRRFC FSGXE GGRSB GJIRD GNWQR GQ7 H13 HF~ HMJXF HRMNR HVGLF HZ~ ITM IWAJR J-C JBSCW JZLTJ KOV LLZTM M4Y NQJWS NU0 O9- P2P R9I RLLFE ROL RSV S1Z S27 S3A S3B SBL SBY SCLPG SHX SISQX SJYHP SNPRN SNX SOHCF SOJ SPKJE SRMVM SSLCW T13 TSG U2A U9L UG4 UTJUX UZXMN VC2 VDBLX VFIZW W48 WK8 Z45 ~A9 ~JE IQODW -EM 2JN AAYOK ADFZG ADINQ CGR CUY CVF ECM EIF GQ6 NPM SNE Z7U Z87 7X8 |
| ID | FETCH-LOGICAL-c315t-85607026f752dc5c43790f436cabdd98da2646ce30efc83e3ca85613fc4ba3883 |
| ISSN | 0378-7966 |
| IngestDate | Thu Oct 02 10:52:25 EDT 2025 Wed Feb 19 02:43:35 EST 2025 Mon Jul 21 09:16:43 EDT 2025 Wed Oct 01 04:43:13 EDT 2025 Thu Apr 24 23:01:43 EDT 2025 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 4 |
| Keywords | Human Biological fluid Oral administration Pharmacokinetics Huperzine human plasma Blood plasma |
| Language | English |
| License | http://www.springer.com/tdm CC BY 4.0 |
| LinkModel | OpenURL |
| MergedId | FETCHMERGED-LOGICAL-c315t-85607026f752dc5c43790f436cabdd98da2646ce30efc83e3ca85613fc4ba3883 |
| Notes | ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-1 content type line 23 |
| PMID | 18348466 |
| PQID | 70115506 |
| PQPubID | 23479 |
| PageCount | 5 |
| ParticipantIDs | proquest_miscellaneous_70115506 pubmed_primary_18348466 pascalfrancis_primary_20050279 crossref_primary_10_1007_BF03191002 crossref_citationtrail_10_1007_BF03191002 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2007-10-01 |
| PublicationDateYYYYMMDD | 2007-10-01 |
| PublicationDate_xml | – month: 10 year: 2007 text: 2007-10-01 day: 01 |
| PublicationDecade | 2000 |
| PublicationPlace | Genève |
| PublicationPlace_xml | – name: Genève – name: France |
| PublicationTitle | European journal of drug metabolism and pharmacokinetics |
| PublicationTitleAlternate | Eur J Drug Metab Pharmacokinet |
| PublicationYear | 2007 |
| Publisher | Médecine et hygiène |
| Publisher_xml | – name: Médecine et hygiène |
| References | B.C. Qian (BF03191002_CR6) 1995; 16 P. Yue (BF03191002_CR9) 2005; 40 Y.W. Wang (BF03191002_CR8) 2004; 4 Y.X. Li (BF03191002_CR11) 2007; 21 Y.E. Wang (BF03191002_CR7) 1988; 9 C Li (BF03191002_CR10) 2004; 18 J.S. Liu (BF03191002_CR1) 1986; 64 X.C. Tang (BF03191002_CR2) 1986; 7 X.C. Tang (BF03191002_CR3) 1989; 24 X.C. Tang (BF03191002_CR4) 1996; 17 A. Zangara (BF03191002_CR5) 2003; 75 15063351 - J Chromatogr B Analyt Technol Biomed Life Sci. 2004 Apr 25;803(2):375-8 8701751 - Zhongguo Yao Li Xue Bao. 1995 Sep;16(5):396-8 12895686 - Pharmacol Biochem Behav. 2003 Jun;75(3):675-86 9863136 - Zhongguo Yao Li Xue Bao. 1996 Nov;17(6):481-4 2585551 - J Neurosci Res. 1989 Oct;24(2):276-85 17080497 - Biomed Chromatogr. 2007 Jan;21(1):15-20 2955639 - Zhongguo Yao Li Xue Bao. 1986 Nov;7(6):507-11 15052575 - Rapid Commun Mass Spectrom. 2004;18(6):651-6 |
| References_xml | – volume: 24 start-page: 276 year: 1989 ident: BF03191002_CR3 publication-title: J. Neur. Res. doi: 10.1002/jnr.490240220 – volume: 75 start-page: 675 year: 2003 ident: BF03191002_CR5 publication-title: Pharmacol. Biochem. Behav. doi: 10.1016/S0091-3057(03)00111-4 – volume: 4 start-page: 375 year: 2004 ident: BF03191002_CR8 publication-title: J. Chromatogr. B. doi: 10.1016/j.jchromb.2004.01.013 – volume: 40 start-page: 1503 year: 2005 ident: BF03191002_CR9 publication-title: Zhongguo Yaoxue Zazhi – volume: 7 start-page: 507 year: 1986 ident: BF03191002_CR2 publication-title: Acta Pharmacol. Sin. – volume: 16 start-page: 396 year: 1995 ident: BF03191002_CR6 publication-title: Acta Pharmacol. Sin. – volume: 21 start-page: 15 year: 2007 ident: BF03191002_CR11 publication-title: Biomed. Chromatogr. doi: 10.1002/bmc.709 – volume: 64 start-page: 837 year: 1986 ident: BF03191002_CR1 publication-title: Can. J. Chem. doi: 10.1139/v86-137 – volume: 17 start-page: 481 year: 1996 ident: BF03191002_CR4 publication-title: Zhongguo Yaoli Xuebao – volume: 18 start-page: 651 year: 2004 ident: BF03191002_CR10 publication-title: Rapid Commun. Mass Spectrom. doi: 10.1002/rcm.1384 – volume: 9 start-page: 193 year: 1988 ident: BF03191002_CR7 publication-title: Acta Pharmacol. Sin. – reference: 2585551 - J Neurosci Res. 1989 Oct;24(2):276-85 – reference: 12895686 - Pharmacol Biochem Behav. 2003 Jun;75(3):675-86 – reference: 15052575 - Rapid Commun Mass Spectrom. 2004;18(6):651-6 – reference: 17080497 - Biomed Chromatogr. 2007 Jan;21(1):15-20 – reference: 9863136 - Zhongguo Yao Li Xue Bao. 1996 Nov;17(6):481-4 – reference: 8701751 - Zhongguo Yao Li Xue Bao. 1995 Sep;16(5):396-8 – reference: 15063351 - J Chromatogr B Analyt Technol Biomed Life Sci. 2004 Apr 25;803(2):375-8 – reference: 2955639 - Zhongguo Yao Li Xue Bao. 1986 Nov;7(6):507-11 |
| SSID | ssj0000389556 |
| Score | 1.8523632 |
| Snippet | The objective of the present study was to investigate the in vivo pharmacokinetics of huperzine A in healthy human volunteers. Twelve subjects (M 6, F 6; age... |
| SourceID | proquest pubmed pascalfrancis crossref |
| SourceType | Aggregation Database Index Database Enrichment Source |
| StartPage | 183 |
| SubjectTerms | Administration, Oral Adult Alkaloids Area Under Curve Biological and medical sciences Cholinesterase Inhibitors - administration & dosage Cholinesterase Inhibitors - blood Cholinesterase Inhibitors - pharmacokinetics Chromatography, High Pressure Liquid Female Half-Life Humans Male Mass Spectrometry Medical sciences Pharmacology. Drug treatments Sesquiterpenes - administration & dosage Sesquiterpenes - blood Sesquiterpenes - pharmacokinetics Tablets |
| Title | Pharmacokinetics of huperzine A following oral administration to human volunteers |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/18348466 https://www.proquest.com/docview/70115506 |
| Volume | 32 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVLSH databaseName: SpringerLink Journals customDbUrl: mediaType: online eissn: 2107-0180 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0000389556 issn: 0378-7966 databaseCode: AFBBN dateStart: 19970301 isFulltext: true providerName: Library Specific Holdings – providerCode: PRVAVX databaseName: SpringerLINK - Czech Republic Consortium customDbUrl: eissn: 2107-0180 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0000389556 issn: 0378-7966 databaseCode: AGYKE dateStart: 19970101 isFulltext: true titleUrlDefault: http://link.springer.com providerName: Springer Nature – providerCode: PRVAVX databaseName: SpringerLink Journals (ICM) customDbUrl: eissn: 2107-0180 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0000389556 issn: 0378-7966 databaseCode: U2A dateStart: 19970101 isFulltext: true titleUrlDefault: http://www.springerlink.com/journals/ providerName: Springer Nature |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1ta9swEBZZ92Uwyt6XbusEG4WR2tixbMkfQ9lICxvtSCDfgq2XbqwkIbEZ2W_Yj97JkqU5y9jLFxOMYhvdo9Pd6e45hF7HnDIZkzRgLBEBIYIHJc0LMOSYpncrKeU6NPD-QzaekotZOuv1vv-UtVRXZci_7a0r-R-pwj2Qq66S_QfJuofCDfgN8oUrSBiufyXjS8s7_QVMxYZuWVt-9UquNWU0LHkFQl5-bfKadR1-0SHK1Van6dCnNRTMr82F3xuntzarWNfXuuk0IOem7a6x2vkIl-Jz3qj3cDBzwenxyFRIfQwHV91hZ6HPXLw4t8NmoS2daKMS1OW32cwkc8wvpM4OGMhq8Gl7_bm5x2y2gK3ZAh-W5qbvSquPfbzTBxsa5Rqbljd2n47NRv3LFhC5xHZwRaNo6De69nB_Z_9zWYk6wAZeen4L3R7CHqEbgUyHIxex01SEaWoOv-1nd_lu7Qs7Fs7dVbGBxaZMl5TfuzGNOTO5hw6tH4JHBlT3UU8uHqATC6jtKZ74urzNKT7Bl57ifPsQXe0iDy8VdsjDI-yQhzXycBd5uFriBnnYI-8Rmr57OzkbB7Y5R8CTOK0CBqYyBQde0XQoeMo1r2WkSJLxohQiZ6IAUzvjMomk4iyRCS-YdlYVJ2WRgGZ4jA4Wy4V8ijDLYsYTViihIkKUyAklvIzh_1HJY5X20Zt2QufcMtfrBio385Zz209-H71yY1eGr2XvqOOOXNzQFgJ99LIV1Bz0rT5EKxZyWW_mVPtQaZT10RMjP_8alhCw5rOjPz38Gbrjl8xzdFCta_kCTNuqPG4Q9wMp56Lz |
| linkProvider | Springer Nature |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Pharmacokinetics+of+huperzine+A+following+oral+administration+to+human+volunteers&rft.jtitle=European+journal+of+drug+metabolism+and+pharmacokinetics&rft.au=LI%2C+Y.+X&rft.au=ZHANG%2C+R.+Q&rft.au=LI%2C+C.+R&rft.au=JIANG%2C+X.+H&rft.date=2007-10-01&rft.pub=M%C3%A9decine+et+hygi%C3%A8ne&rft.issn=0378-7966&rft.volume=32&rft.issue=4&rft.spage=183&rft.epage=187&rft_id=info:doi/10.1007%2FBF03191002&rft.externalDBID=n%2Fa&rft.externalDocID=20050279 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0378-7966&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0378-7966&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0378-7966&client=summon |